You are here:

exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta)

Advice

Following a full submission

exenatide (Byetta®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in combination with metformin and/or sulphonylureas in patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

It has shown non-inferiority to two insulin regimens with which it has been compared and has a beneficial effect on weight. It is restricted to use as an alternative to insulin in patients who have failed treatment on metformin and/or sulphonylureas and in whom insulin would be the next treatment option.

Drug Details

Drug Name: exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta)
SMC Drug ID: 376/07
Manufacturer: Eli Lilly and Company Ltd
Indication: Type 2 diabetes mellitus
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 July 2007

Back